Abeona Therapeutics

News

Abeona Therapeutics' Zevaskyn has been approved in the US as a treatment for the rare skin disorder recessive dystrophic epidermolysis bullosa (DEB).

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.